Dr. Heidi Wang graduated from the University of Notre Dame in Indiana, USA with a M.S. and a Ph.D. in molecular biology and virology. She also received postdoctoral training in cancer biology at the Cold Spring Harbor Laboratory in New York, USA.
Before joining OBI Pharma as the CEO in June 2023, Heidi had a ~30-year career at Bristol-Myers Squibb (BMS, a Fortune 500 company) leading teams in the US headquarter and in multiple countries, including China. Heidi has a proven record of working or leading teams to obtain approvals for 9 New Molecule Entities, many were first-in-class drugs, as well as numerous supplemental applications worldwide.
When in BMS, Heidi had a chance to transform company’s process and mindset to optimize company’s portfolio acceleration, enable global submissions and approvals of life saving medicines, and shape company’s 2030 China strategy, etc. When working as the BMS China regulatory head and acting R&D China head, Heidi successfully delivered four new medicines to patients while navigating the complicated regulatory environment.
Now as the CEO of OBI Pharma, Heidi continues what she did at BMS to change the company’s culture, mindset, and processes, and provide leadership to optimize OBI’s portfolio for patients.